ASH roundup: late breakers take the stage
pharmaphorum
DECEMBER 14, 2022
At ASH, the E1910 clinical trial generated results could unlock a new patient population for Blincyto, after it was shown to improve overall survival in patients with no measurable residual disease (MRD) after induction chemotherapy for B-ALL. At the moment, Blincyto is approved to treat patients with MRD after induction treatment.
Let's personalize your content